[ET Net News Agency, 18 September 2018] Luye Pharma (02186) said the import
registration of the group's innovative drug delivery system drug, rivastigmine transdermal
patch, has been accepted by China National Medical Products Administration (NMPA).
The rivastigmine patch is developed from the transdermal patch research and development
platform of its subsidiary Luye Pharma AG and is used for the treatment of mild to
moderate Alzheimer's disease.
The product penetrates the skin and is absorbed by the body, avoiding the
gastrointestinal discomfort from oral medications and swallowing difficulties of certain
number of patients.
The rivastigmine patch has already been launched in the United States, ten European
countries, as well as Israel, Thailand and other countries. According to IQVIA, the total
sales volume of rivastigmine patch was US$520 million in the United States and Europe in
2017. (SC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02186 LUYE PHARMA
Nominal 
2.700 +0.010 (+0.372%) Others
18/09/2018 09:32
Luye Pharma (02186) Alzheimer's drug registration accepted
| Remark: | Real time quote last updated: 25/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |